A derivative of sorafenib
| Cas No. | 1648546-79-5 |
| Canonical SMILES | O=C(NC1=CC=C(C(Cl)=C1)Cl)NC2=CC=CC(CNC3=C4C=CC=CC4=NC=N3)=C2O=C(NC1=CC=C(C(Cl)=C1)Cl)NC2=CC=CC(CNC3=C4C=CC=CC4=NC=N3)=C2 |
| 分子式 | C22H17Cl2N5O |
| 分子量 | 438.3 |
| 溶解度 | DMF: 1 mg/ml,DMSO: 1 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | CAY10773 is a derivative of the ferroptosis inducer sorafenib .1It selectively inhibits proliferation of BEL-7402, MGC803, and T24 bladder cancer cells (IC50s = 5.77, 5.21 and 3.97 µM, respectively) over non-cancerous HCV-29 cells (IC50= 23.19 µM). CAY10773 induces apoptosis in T24 cells when used at concentrations ranging from 2 to 6 µM but induces ferroptosis at concentrations greater than or equal to 6 µM with 10 hour or longer incubation times. It increases the production of reactive oxygen species (ROS) and decreases the mitochondrial membrane potential in T24 cells. CAY10773 (≥6 µM) also induces autophagy with incubation times longer than eight hours. 1.Chen, J.-N., Li, T., Cheng, L., et al.Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivativesEur. J. Med. Chem.205112661(2020) |
